# DC-HIL in cancer

> **NIH VA I01** · VA NORTH TEXAS HEALTH CARE SYSTEM · 2024 · —

## Abstract

PROJECT SUMMARY
Melanoma is a significant cause of morbidity and mortality in the U.S. and among
military veterans. Having discovered an immune-vascular regulating pathway (DC-
HIL/SD4) whose function can be manipulated to treat cancers, we will: (1) dissect its
effects on immunity and vascularity in melanoma; (2) develop treatment targeted at a
key carbohydrate component of the pathway; and (3) characterize changes in this
component during melanoma growth and metastasis. Our results will improve current
management of metastatic melanoma and potentially other cancers.

## Key facts

- **NIH application ID:** 10721360
- **Project number:** 5I01BX004069-06
- **Recipient organization:** VA NORTH TEXAS HEALTH CARE SYSTEM
- **Principal Investigator:** PONCIANO D CRUZ
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2024
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2018-01-01 → 2026-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10721360

## Citation

> US National Institutes of Health, RePORTER application 10721360, DC-HIL in cancer (5I01BX004069-06). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10721360. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*